Compare IRTC & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRTC | IDYA |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2016 | 2019 |
| Metric | IRTC | IDYA |
|---|---|---|
| Price | $109.33 | $32.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | ★ $172.14 | $52.29 |
| AVG Volume (30 Days) | 449.9K | ★ 840.4K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.71 | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $747,138,000.00 | $218,710,000.00 |
| Revenue This Year | $19.40 | N/A |
| Revenue Next Year | $16.65 | $189.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 26.24 | ★ 3024.43 |
| 52 Week Low | $100.70 | $26.81 |
| 52 Week High | $210.01 | $42.68 |
| Indicator | IRTC | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 27.61 |
| Support Level | $107.33 | $29.74 |
| Resistance Level | $117.56 | $35.14 |
| Average True Range (ATR) | 3.63 | 1.29 |
| MACD | 0.44 | -0.43 |
| Stochastic Oscillator | 66.94 | 5.25 |
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.